Market Closed -
Nasdaq
04:30:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.5787
USD
|
-3.55%
|
|
+57.13%
|
-34.98%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
---|
Capitalization
1 |
387.4
|
123.2
|
65.83
|
Enterprise Value (EV)
1 |
395.7
|
145.6
|
74.63
|
P/E ratio
|
-4.81
x
|
-0.89
x
|
-0.61
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
18.9
x
|
6.85
x
|
5.47
x
|
EV / Revenue
|
19.3
x
|
8.1
x
|
6.2
x
|
EV / EBITDA
|
-4.39
x
|
-1.43
x
|
-0.94
x
|
EV / FCF
|
-11,875,793
x
|
-4,295,502
x
|
-3,104,424
x
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
Price to Book
|
141
x
|
-27.5
x
|
-8.33
x
|
Nbr of stocks (in thousands)
|
560
|
795
|
2,039
|
Reference price
2 |
691.7
|
155.0
|
32.28
|
Announcement Date
|
4/30/21
|
5/16/22
|
5/16/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
5.686
|
10.25
|
10.84
|
20.51
|
17.99
|
12.04
|
EBITDA
1 |
-38.92
|
-40.72
|
-86.45
|
-90.06
|
-102.2
|
-79.46
|
EBIT
1 |
-40.92
|
-43.61
|
-89.08
|
-93.13
|
-106
|
-84.14
|
Operating Margin
|
-719.72%
|
-425.45%
|
-821.41%
|
-454.07%
|
-589.6%
|
-698.59%
|
Earnings before Tax (EBT)
1 |
-39.31
|
-42.5
|
-101.8
|
-80.65
|
-121.3
|
-105.7
|
Net income
1 |
-39.08
|
-42.06
|
-101.1
|
-80.48
|
-118.7
|
-101.9
|
Net margin
|
-687.23%
|
-410.37%
|
-931.86%
|
-392.39%
|
-659.93%
|
-846.01%
|
EPS
2 |
-98.46
|
-98.69
|
-226.1
|
-143.8
|
-174.5
|
-53.29
|
Free Cash Flow
|
-
|
-17.93
|
-25.21
|
-33.32
|
-33.9
|
-24.04
|
FCF margin
|
-
|
-174.92%
|
-232.45%
|
-162.46%
|
-188.5%
|
-199.59%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/20/19
|
9/20/19
|
5/15/20
|
4/30/21
|
5/16/22
|
5/16/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
4.17
|
40.9
|
34.6
|
8.32
|
22.5
|
8.8
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-0.107
x
|
-1.005
x
|
-0.4007
x
|
-0.0924
x
|
-0.2198
x
|
-0.1107
x
|
Free Cash Flow
|
-
|
-17.9
|
-25.2
|
-33.3
|
-33.9
|
-24
|
ROE (net income / shareholders' equity)
|
-
|
656%
|
530%
|
1,274%
|
-5,227%
|
2,562%
|
ROA (Net income/ Total Assets)
|
-
|
-48.3%
|
-105%
|
-113%
|
-113%
|
-97.4%
|
Assets
1 |
-
|
87.13
|
95.97
|
71.12
|
105.1
|
104.6
|
Book Value Per Share
2 |
22.40
|
-52.10
|
-32.40
|
4.890
|
-5.630
|
-3.870
|
Cash Flow per Share
2 |
26.80
|
30.00
|
12.40
|
5.000
|
11.60
|
0.5300
|
Capex
1 |
2.6
|
2.42
|
2.79
|
2.47
|
3.9
|
1.46
|
Capex / Sales
|
45.8%
|
23.58%
|
25.73%
|
12.02%
|
21.68%
|
12.1%
|
Announcement Date
|
9/20/19
|
9/20/19
|
5/15/20
|
4/30/21
|
5/16/22
|
5/16/23
|
|
1st Jan change
|
Capi.
|
---|
| -34.98% | 12.86M | | -20.45% | 10.82B | | +43.17% | 3.25B | | -35.86% | 2.11B | | -17.21% | 2.08B | | -29.81% | 1.48B | | +17.56% | 1.02B | | -4.37% | 733M | | -37.00% | 391M | | -46.94% | 377M |
Bio Diagnostics & Testing
|